Breast Cancer Treatment Protocols: Systematic Review of the Last 35 Years


  • Thais Ligiero Braga Military Hospital Marcilio Dias, Nuclear Medicine Division, Rio de Janeiro, Brazil
  • Filipe Leal Portilho Brazilian Nuclear Energy Commssion, Nuclear Enginerring Institute, Rio de Janeiro, Brazil
  • Ralph Santos-Oliveira Brazilian Association of Radiopharmacy, Presidency, Rio de Janeiro, Brazil



Breast cancer, protocols, systematic review.


 Breast cancer is the main leading type of cancer for women around the world and is responsible for 522,000 deaths per year worldwide. In order to reduce this number, clinicians and researchers are always looking for new strategies and protocols. However, the treatment for breast cancer is challenging and requires as much information as possible. To this end, we conducted a review of all protocols used for breast cancer treatment in the last 35 years with the objective to help clinicians to choose the best treatment possible available in their region. Many of the protocols are international references, and for that reason have been used in many countries like USA and Europe. The data, depicted in tables, may be helpful for clinicians worldwide and researchers to better understand the evolution of breast cancer protocols such as helping make daily routine decisions.


Miller DK, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66: 271-289.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1): 7-30.

Scalia-Wilbur J, et al. Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2. Semin Radiat Oncol 2016; 26(1): 3-8.

Tang Y, et al. Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. Clin Breast Cancer 2016; pii: S1526-8209(16)30108-2.

Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368.

Abramovitz M, et al. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer. Clin Breast Cancer 2016; pii: S1526-8209(16)30146-X.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.

Bernier J, et al. Surgery and radiation therapy of triplenegative breast cancers: From biology to clinics. Breast 2016; 28: 148-55.

Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med 2002; 21: 3511-3526.

DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252-271.

Bhargava A, Du XL. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer 2009; 115: 2999-3008.

McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol 2009; 16: 2682-2690.

Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 2015; 150: 9-16.

Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-1792.

Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 2016; 34: 611-635.

Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104: 386-405.




How to Cite

Thais Ligiero Braga, Filipe Leal Portilho, & Ralph Santos-Oliveira. (2017). Breast Cancer Treatment Protocols: Systematic Review of the Last 35 Years. Journal of Analytical Oncology, 6(2),  57–102.